|
Total: $137.95M Year to Date: $240.23M | ||||
Company (Location) |
Partner (Location) |
Amt. (M) |
Details |
Date |
Ablynx NV (Ghent, Belgium) |
Boehringer Ingelheim GmbH (Ingelheim, Germany) |
$1 |
For the submission of a clinical trials application in Europe to start a Phase I trial of a Nanobody for Alzheimer's disease |
4/26/12 |
Ablynx NV (Ghent, Belgium) |
Novartis AG (Basel, Switzerland) |
€0.4 ($0.531) |
For the approval of an investigational new drug application for a Phase I trial of a Nanobody licensed to Novartis under a 2010 agreement |
4/3/12 |
Affymax Inc. (Palo Alto, Calif.) |
Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) |
$50 |
For the FDA approval of Omontys to treat anemia in adult dialysis patients with chronic kidney disease |
4/11/12 |
BioDelivery Sciences International Inc. (Raleigh, N.C.) |
Endo Pharmaceuticals Holdings Inc. (Chadds Ford, Pa.) |
$15 |
For BioDelivery receiving a patent extension for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone for seven additional years, to 2027 |
4/18/12 |
Incyte Corp. (Wilmington, Del.) |
Novartis AG (Basel, Switzerland) |
$40 |
For the positive recommendation by the European Committee for Medicinal Products for Human Use for JAK inhibitor ruxolitinib in disease-related slenomegaly or symptoms in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis for post-essential thrombocythemia myelofibrosis |
4/23/12 |
Photocure ASA (Oslo, Norway) |
Ipsen SA (Paris) |
€0.75 ($0.982) |
For the third and final manufacturing transition milestone from Ipsen to commercialize Hexvix worldwide |
4/12/12 |
Summit plc (Oxford, UK) |
U.S.-based DMD organizations |
$0.4375 |
For approval of a Phase I trial application for SMT C1100 for Duchenne's muscular dystrophy |
4/25/12 |
Threshold Pharmaceuticals Inc. (South San Francisco) |
Merck KGaA (Darmstadt, Germany) |
$20 |
For results showing significant benefit for progression-free survival in a trial comparing TH-302 with gemcitabine to gemcitabine alone in 214 pancreatic cancer patients |
4/12/12 |
Vical Inc. (San Diego) |
Astellas Pharma Inc. (Tokyo) |
$10 |
For finalizing the design for a pivotal Phase III trial of TransVax cytomegalovirus vaccine for transplant recipients |
4/3/12 |
Xencor Inc. (Monrovia, Calif.) |
Boehringer Ingelheim GmbH (Ingelheim, Germany) |
ND |
For a regulatory submission to begin Phase I trials of a monoclonal antibody optimized using Xencor's XmAb antibody engineering technology |
4/5/12 |
Xencor Inc. (Monrovia, Calif.) |
CSL Ltd. (Melbourne, Australia) |
ND |
For CSL's filing of an investigational new drug application with the FDA for a monoclonal antibody optimized with Xencor's XmAb antibody engineering technology |
4/20/12 |
|
Notes: Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. | ||||